News

Published on 22 Apr 2024 on Zacks via Yahoo Finance

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

Article preview image

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar I disorder) that are witnessing a steady uptake and driving growth.

The continued growth in the alcohol-dependence treatment market has driven new patients toward Vivitrol, while Aristada sales have been driven by underlying demand in recent quarters.

Read the rest of the article
NASDAQ.ALKS price evolution
NASDAQ.ANIP price evolution
NASDAQ.ADMA price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
ADMA Biologics Inc (ADMA) Q3 2024 Earnings Call Highlights: Record Revenue and...

ADMA Biologics Inc (ADMA) reports a 78% revenue increase and a 1,300% rise in net income, while...

GuruFocus.com · via Yahoo Finance 8 Nov 2024
ADMA Biologics Inc (ADMA) Q3 2024: Everything You Need To Know Ahead Of Earnings

ADMA Biologics Inc (NASDAQ:ADMA) is set to release its Q3 2024 earnings on Nov 7, 2024. The...

GuruFocus.com · via Yahoo Finance 6 Nov 2024
ADMA Biologics Inc (ADMA) Q2 2024 Earnings Call Highlights: Record Revenue and...

Total Revenue: $107.2 million for Q2 2024, a 78% increase year-over-year.Adjusted EBITDA: $44.5 m...

GuruFocus.com · via Yahoo Finance 6 Oct 2024
Is ADMA Biologics Inc. (ADMA) the Best Performing Small-Cap Stock in 2024?

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, ...

Insider Monkey · via Yahoo Finance 29 Sep 2024
ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Could Be 36% Below Their Intrinsic...

Key Insights The projected fair value for ADMA Biologics is US$16.66 based on 2 Stage Free Cash F...

Simply Wall St. · via Yahoo Finance 18 Jun 2024
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Call Transcript

ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Call Transcript May 9, 2024 ADMA Biologics, I...

Insider Monkey via Yahoo Finance 10 May 2024
ADMA Biologics Inc (ADMA) Surpasses Analyst Revenue and Earnings Forecasts in Q1 2024

Revenue: Reported $81.9 million, a 44% increase year-over-year, surpassing estimates of $77.28 mi...

GuruFocus.com via Yahoo Finance 10 May 2024
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day...

Shares of Diodes Incorporated DIOD fell sharply during Friday's session after the company reporte...

Benzinga 10 May 2024
ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results - ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics, Inc. ADMA reported better-than-expected first-quarter financial results and issue...

Benzinga 10 May 2024
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?

We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s ADMA portfolio of...

Zacks via Yahoo Finance 29 Apr 2024

Copyright Statfolio @ 2024

Social Accounts